Aurion Biotech wins Prix Galien Award for corneal endothelial dystrophy cell therapy
Click Here to Manage Email Alerts
Aurion Biotech has won the Prix Galien Award for Best Startup in Biotech/Pharma, recognizing the company’s clinically validated cell therapy for corneal endothelial dystrophies, according to a press release.
“We are so grateful to the Prix Galien Awards Committee for conferring this incredible award on Aurion Biotech,” Greg Kunst, MBA, president and CEO of Aurion Biotech, told Healio/OSN. “We believe it’s a tribute to our patients, employees, scientists and physicians who are collaborating to bring this transformational cell therapy to millions of people suffering from corneal endothelial diseases.”
The Prix Galien is an international awards program created in 1970 to recognize innovative medicines development. Aurion Biotech was selected as the winner of the Best Start-up in Biotech/Pharma category among 146 products from 129 companies spanning 14 therapeutic areas.
Aurion Biotech’s cell therapy for corneal edema secondary to endothelial dysfunction is one of the first clinically validated cell therapies for corneal care. Only a few ophthalmology products have been awarded the Prix Galien in the past, according to the release.
Read more about
Click Here to Manage Email Alerts